Skip to main content

Qing Cheng, PhD

Associate Professor in Surgery
Office: 203 Research Drive, 452 Msrb1, Durham, NC 27710
Campus Mail: DUMC Duke Box 2606, Durham, NC 27710

My research has been focusing on the development of methodologies and strategies to address the general question of human cancer heterogeneity and complexity, recognizing that clinical outcomes reflect a combination of contribution from the actual tumor but also the environment in which the tumor resides. By understanding who is at risk for recurrence, who is likely to respond to a given agent or regimen, and who is likely to exhibit an adverse event associated with a particular therapy, it will be possible to tailor therapeutic strategies to the characteristics of the individual patient as opposed to relying on the results of studies with heterogeneous populations of patients.

I made the original observation that gene copy number alterations (CNAs) in malignant cells can quantitatively affect gene function (Nat Genet 2005), and the contribution of this work to the field of cancer pharmacogenomics and personalized medicine was highly recognized by a "NEWS AND VIEWS" paper of Nature Genetics, in 2005. I demonstrated that clinical phenotypes can be affected by multiple forms of alterations (methylation, mutation, CNA) (Am J Hum Genet 2006), and genome-scan of CNAs followed by pathway analysis could uncover the novel gene interactions (Nat Med 2011). We developed a methodology that compiled a large collection of genomic data (Breast Cancer Res 2012) and demonstrated that uniquely characteristic of a clinical phenotype, such as dormancy, could be accessed using gene signature, a collection of multiple genetic alterations (Breast Cancer Res 2014).

Education and Training

  • Postdoctoral Research Associate, St. Jude Children's Research Hospital, 2001 - 2006
  • Ph.D., National University of Singapore (Singapore), 2001

Publications

Liu, Zheng, Kejia Zhao, Shiyou Wei, Chengwu Liu, Jiankang Zhou, Qiheng Gou, Xia Wu, et al. “ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.” Oncoimmunology 9, no. 1 (May 6, 2020): 1758003. https://doi.org/10.1080/2162402X.2020.1758003.

Full Text

Shaw, Brian I., Daniel K. Cheng, Chaitanya R. Acharya, Robert B. Ettenger, Herbert Kim Lyerly, Qing Cheng, Allan D. Kirk, and Eileen T. Chambers. “An age-independent gene signature for monitoring acute rejection in kidney transplantation.” Theranostics 10, no. 15 (2020): 6977–86. https://doi.org/10.7150/thno.42110.

Full Text

Li, Yanjing, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, et al. “Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.” Sci Transl Med 11, no. 521 (December 4, 2019). https://doi.org/10.1126/scitranslmed.aax0428.

Full Text

Shaw, B. I., D. K. Cheng, Q. Cheng, C. R. Acharya, A. D. Kirk, and E. T. Chambers. “A Novel Genomic Approach for Acute Rejection across All Age Groups in Kidney Transplantation.” In American Journal of Transplantation, 19:519–519. WILEY, 2019.

Scholars@Duke

Cheng, Qing, Xuechan Li, Chaitanya R. Acharya, Terry Hyslop, and Julie Ann Sosa. “A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.” Oncotarget 8, no. 10 (March 7, 2017): 16690–703. https://doi.org/10.18632/oncotarget.15128.

Full Text

Price, Trevor T., Monika L. Burness, Ayelet Sivan, Matthew J. Warner, Renee Cheng, Clara H. Lee, Lindsey Olivere, et al. “Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.” Sci Transl Med 8, no. 340 (May 25, 2016): 340ra73. https://doi.org/10.1126/scitranslmed.aad4059.

Full Text

Price, Trevor T., Clara H. Lee, Qing Cheng, H Kim Lyerly, William E. Fogler, John L. Magnani, and Dorothy A. Sipkins. “Abstract 3212: Metastatic breast cancer cell communication within a pro-dormancy bone marrow niche.” In Tumor Biology. American Association for Cancer Research, 2015. https://doi.org/10.1158/1538-7445.am2015-3212.

Full Text

Gwin, William Rayford, Amy Hobeika, Takuya Osada, Zachary Hartman, Qing Cheng, Gloria Broadwater, Gretchen Genevieve Kimmick, Kimberly L. Blackwell, Michael Morse, and Kim Lyerly. “Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.” In Journal of Clinical Oncology, 33:3081–3081. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3081.

Full Text

Yang, L. -. P., A. -. L. Zhang, D. -. D. Wang, H. -. X. Ke, Q. Cheng, and C. Wang. “Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin.” J Clin Pharm Ther 39, no. 4 (August 2014): 442–45. https://doi.org/10.1111/jcpt.12159.

Full Text

Cheng, Qing, Jeffrey T. Chang, William R. Gwin, Jun Zhu, Stefan Ambs, Joseph Geradts, and H Kim Lyerly. “A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.” Breast Cancer Res 16, no. 4 (July 25, 2014): 407. https://doi.org/10.1186/s13058-014-0407-9.

Full Text

Pages